-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There is a huge and potential development space in the Chinese pharmaceutical market, attracting many multinational pharmaceutical companies to develop and deploy in China
.
In order to introduce more innovative drugs to China, as early as November 2019, the multinational pharmaceutical company AstraZeneca announced a strategic cooperation with Shanghai to upgrade the existing AstraZeneca Shanghai R&D platform to a global R&D center
.
After nearly two years, this goal has finally been achieved
.
In recent news, AstraZeneca announced the official opening of its global R&D center in China.
At the same time, the Shanghai International Life Science Innovation Park, a one-stop innovation enabling platform, and a medical artificial intelligence innovation center that accelerate the application of AI technology in the medical field, will accelerate more in the future Innovative drugs and solutions are incubated in China and benefit patients worldwide
.
According to reports, AstraZeneca’s Global R&D China Center will be deeply involved in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch, covering tumors, respiratory, immune, cardiovascular, and kidney , Metabolism, rare diseases and other broad disease fields, realize the simultaneous research and development of new drugs around the world, and further solve China’s unmet medical needs
.
At the same time, the Global R&D China Center will use independent R&D and external cooperation models to accelerate the introduction of global innovative drugs into China, and at the same time accelerate the development of local innovative drugs and bring them to the world, to provide global patients with world-class "Made in China" high-quality medical care The solution
.
It is understood that since AstraZeneca entered China in 1993, it has been deeply involved in the Chinese market for 28 years.
There are more than 120 research projects in the R&D pipeline in China, and more than 85% of the projects developed simultaneously in the global pipeline
.
The focus of the Global R&D China Center has shifted from conducting confirmatory research in China and supporting the launch of new drugs to earlier research and development
.
Biomedicine is an important pillar of Shanghai's strategic emerging industries.
At present, it has formed a "1+5+X" industrial development layout centered on Zhangjiang, supported by 5 characteristic parks including Lingang New Area, and supplemented by other characteristic bases.
, The linkage development pattern of "Zhangjiang R&D + Shanghai Manufacturing" is continuously optimized
.
According to data, in 2020, the scale of Shanghai's biomedical industry will exceed 600 billion yuan, of which the total output value of related industries will exceed 140 billion yuan..
In addition, the industrial scale in the first half of this year also exceeded 350 billion yuan, a year-on-year increase of 22.
8%
.
At present, Shanghai foreign-funded biopharmaceutical companies account for about 60% of the total.
More than 10 large multinational pharmaceutical companies including Roche have settled in Shanghai, and have established Chinese headquarters, R&D centers or production bases in Shanghai
.
As AstraZeneca's global R&D center in China sets sail in Shanghai, it will also help more innovative drugs in China "go global", speed up integration with internationalization, and benefit patients worldwide
.
At the same time, it also adds vitality to the development of Shanghai's biomedical industry and contributes to Shanghai's creation of a world-class biomedical industry highland
.
According to Shanghai's plan, the city will promote the development of the biomedical industry in three aspects in the future, namely, researching core technologies, strengthening the layout of frontier fields, and strengthening the transformation of innovative achievements
.
And strive to reach 1.
2 trillion yuan in the city's biomedical industry scale by 2025, and achieve a batch of key core technologies that can be independently controlled, and innovative results can achieve significant results
.
.
In order to introduce more innovative drugs to China, as early as November 2019, the multinational pharmaceutical company AstraZeneca announced a strategic cooperation with Shanghai to upgrade the existing AstraZeneca Shanghai R&D platform to a global R&D center
.
After nearly two years, this goal has finally been achieved
.
In recent news, AstraZeneca announced the official opening of its global R&D center in China.
At the same time, the Shanghai International Life Science Innovation Park, a one-stop innovation enabling platform, and a medical artificial intelligence innovation center that accelerate the application of AI technology in the medical field, will accelerate more in the future Innovative drugs and solutions are incubated in China and benefit patients worldwide
.
According to reports, AstraZeneca’s Global R&D China Center will be deeply involved in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch, covering tumors, respiratory, immune, cardiovascular, and kidney , Metabolism, rare diseases and other broad disease fields, realize the simultaneous research and development of new drugs around the world, and further solve China’s unmet medical needs
.
At the same time, the Global R&D China Center will use independent R&D and external cooperation models to accelerate the introduction of global innovative drugs into China, and at the same time accelerate the development of local innovative drugs and bring them to the world, to provide global patients with world-class "Made in China" high-quality medical care The solution
.
It is understood that since AstraZeneca entered China in 1993, it has been deeply involved in the Chinese market for 28 years.
There are more than 120 research projects in the R&D pipeline in China, and more than 85% of the projects developed simultaneously in the global pipeline
.
The focus of the Global R&D China Center has shifted from conducting confirmatory research in China and supporting the launch of new drugs to earlier research and development
.
Biomedicine is an important pillar of Shanghai's strategic emerging industries.
At present, it has formed a "1+5+X" industrial development layout centered on Zhangjiang, supported by 5 characteristic parks including Lingang New Area, and supplemented by other characteristic bases.
, The linkage development pattern of "Zhangjiang R&D + Shanghai Manufacturing" is continuously optimized
.
According to data, in 2020, the scale of Shanghai's biomedical industry will exceed 600 billion yuan, of which the total output value of related industries will exceed 140 billion yuan..
In addition, the industrial scale in the first half of this year also exceeded 350 billion yuan, a year-on-year increase of 22.
8%
.
At present, Shanghai foreign-funded biopharmaceutical companies account for about 60% of the total.
More than 10 large multinational pharmaceutical companies including Roche have settled in Shanghai, and have established Chinese headquarters, R&D centers or production bases in Shanghai
.
As AstraZeneca's global R&D center in China sets sail in Shanghai, it will also help more innovative drugs in China "go global", speed up integration with internationalization, and benefit patients worldwide
.
At the same time, it also adds vitality to the development of Shanghai's biomedical industry and contributes to Shanghai's creation of a world-class biomedical industry highland
.
According to Shanghai's plan, the city will promote the development of the biomedical industry in three aspects in the future, namely, researching core technologies, strengthening the layout of frontier fields, and strengthening the transformation of innovative achievements
.
And strive to reach 1.
2 trillion yuan in the city's biomedical industry scale by 2025, and achieve a batch of key core technologies that can be independently controlled, and innovative results can achieve significant results
.
